Charles River Laboratories International (NYSE:CRL) said it has reached an agreement to acquire PathoQuest SAS from healthcare-focused private equity firm SHS Capital, together with its co-investors.
The deal is intended to bring together PathoQuest’s proprietary next-generation sequencing technology with Charles River’s global platform, a move that is expected to speed up the broader use of advanced, animal-free biotesting solutions across the sector.
Financial details of the transaction were not disclosed, and the companies did not specify when the acquisition is expected to close.